Medrio Announces Multi-Year Enterprise Agreement with Deep Intelligent Pharma (DIP) for eSuite of Services

Tuesday, March 26, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

The collaboration will create additional value for pharma R&D clients globally including China, Japan, Australia, the United States, and EMEA.

SAN FRANCISCO, Mar. 26, 2019 /PRNewswire-PRWeb/ -- Xing Li, The founder and CEO of Deep Intelligent Pharma (DIP), and

Shinya Yamamoto, The Managing Director of Medrio, Inc., Asia-Pacific Region, announced a strategic alliance between DIP and Medrio at DIP's Beijing office. The collaboration and the application of cutting-edge artificial intelligence (AI) technologies in the clinical trial process will create additional value for pharma R&D clients globally including China, Japan, Australia, the United States, and EMEA. The engagement will benefit both parties with a highly complementary portfolio, and will enable the use of AI for global clinical trials.

As leading innovative companies in AI+ new drug development, DIP and Medrio will launch a full-scale cooperation in the introduction of technology, market expansion, site development, product integration, and intellectualization. In the future, the two companies will jointly provide the Chinese market with an internationally advanced full-module clinical integration platform, which includes clinical systems like Medrio EDC, ePRO, eSource, and eConsent, enabling a closed data loop. In addition, a variety of DIP AI platforms, including the pharmacovigilance product DEEP-PV, will form seamless connections with Medrio systems so that intelligent ecological expansion will be realized for the entire product series, and all global partners can enjoy a full-course solution from clinical data capture, analysis, and management, to safety and pharmacovigilance.

"We are excited to announce a partnership with an innovative global organization such as DIP," commented Steve Geffon, Chief Commercial Officer of Medrio, "The partnership exemplifies the investment and commitment Medrio has made in the APAC region and we look forward to continued growth within APAC led by Shinya Yamamoto."

DIP is now collaborating with a number of clinical sites to prepare for pilot clinical sites empowered by novel intelligent technologies. The "DIP + Medrio" full-module solution will be fully launched for qualified bases, so as to advance at maximum speed towards a next-generation base for clinical trials.

About Deep Intelligent Pharma Founded in 2017, DIP is an innovative high-tech company dedicated to empowering full-process new drug research and development, and accelerating the intellectualization of global pharmaceutical companies and their service providers with artificial intelligence technologies. The team is composed of AI experts from top IT firms and pharmaceutical R&D experts from multinational corporations. DIP's independently developed AI system and relevant services already cover the whole chain of new drug development, including drug discovery, organic synthesis, clinical trials, pharmacovigilance, registration, translation, etc. In Sept., 2018, DIP received an exclusive Series B investment from Sequoia Capital of approx. USD 15 million. Currently, DIP is providing services to over 50 top-rank pharmaceutical and medical device companies, CROs, and third-party organizations around the world. For more information, please visit http://www.dip-ai.com.

About Medrio Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.

 

SOURCE Medrio



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store